Stammdaten
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Unternehmen & Branche
| Name | ABVC BIOPHARMA, INC. |
|---|---|
| Ticker | ABVC |
| CIK | 0001173313 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,9 Mio. USD |
| Beta | 0,38 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -7,908,554 | -0.39 | 21,062,203 | 11,111,861 | |
| 2025-09-30 | 10-Q | 795,950 | -1,246,513 | -0.05 | 21,176,299 | 12,057,619 |
| 2025-06-30 | 10-Q | -2,257,022 | -0.13 | 16,241,060 | 7,013,635 | |
| 2025-03-31 | 10-Q | -842,075 | -0.06 | 14,875,699 | 5,404,386 | |
| 2024-12-31 | 10-K | 509,589 | -4,902,878 | -0.42 | 7,539,907 | 1,226,140 |
| 2024-09-30 | 10-Q | 389,276 | -394,769 | -0.03 | 7,777,705 | 1,642,038 |
| 2024-06-30 | 10-Q | 117,142 | -942,336 | -0.08 | 8,044,434 | 1,786,202 |
| 2024-03-31 | 10-Q | 1,205 | -2,834,199 | -0.29 | 7,976,010 | 1,699,551 |
| 2023-12-31 | 10-K | 152,430 | -7,788,050 | -1.80 | 7,784,499 | 1,554,110 |
| 2023-09-30 | 10-Q | 15,884 | -3,317,516 | -0.82 | 16,591,507 | 9,099,855 |
| 2023-06-30 | 10-Q | 6,109 | -2,263,511 | -0.68 | 9,320,407 | -379,315 |
| 2023-03-31 | 10-Q | 128,272 | -1,823,695 | -0.55 | 10,734,937 | 1,670,488 |
| 2022-12-31 | 10-K | 969,783 | -16,423,239 | -5.19 | 9,579,574 | 3,098,585 |
| 2022-09-30 | 10-Q | 42,269 | -3,704,864 | -1.14 | 10,480,567 | 5,918,681 |
| 2022-06-30 | 10-Q | 312,860 | -1,858,997 | -0.59 | 13,782,612 | 9,334,324 |
| 2022-03-31 | 10-Q | 25,660 | -5,995,440 | -0.20 | 12,066,755 | 7,426,877 |
| 2021-12-31 | 10-K | 355,797 | -12,838,813 | -0.51 | 13,698,033 | 8,843,653 |
| 2021-09-30 | 10-Q | 98,999 | -1,806,488 | -0.07 | 12,354,816 | 8,593,978 |
| 2021-06-30 | 10-Q | 31,441 | -1,971,566 | -0.08 | 8,944,966 | 1,440,470 |
| 2021-03-31 | 10-Q | 263,150 | -1,195,323 | -0.05 | 10,526,062 | 2,571,715 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.